Gold prices bounce off 3-week lows; demand likely longer term
Kim Hyong, the Chief Medical (TASE:BLWV) Officer of Alignment Healthcare, Inc. (NASDAQ:ALHC), recently reported transactions involving the company’s common stock. The healthcare company, currently valued at $2.94 billion, has seen remarkable performance with a 183% return over the past year. According to InvestingPro analysis, the stock is trading near its 52-week high of $16.25. On March 4, 2025, Hyong acquired 58,400 shares at no cost, following the achievement of certain performance objectives. This acquisition increased his holdings to 528,896 shares.
Subsequently, Hyong sold a total of 21,020 shares in two separate transactions. On March 5, he sold 13,394 shares at an average price of $15.7189 per share. The following day, he sold an additional 7,626 shares at an average price of $15.53 per share. These sales, amounting to approximately $328,970, were primarily executed to cover tax obligations related to the vesting of performance share units. After these transactions, Hyong’s total holdings in the company stood at 507,876 shares.
In other recent news, Alignment Healthcare reported its fourth-quarter 2024 earnings, surpassing analysts’ expectations with an EPS of -0.16, compared to the forecast of -0.18. The company’s revenue also exceeded projections, reaching $701.2 million against the expected $674.97 million. This performance highlights the company’s ability to consistently exceed market predictions. Piper Sandler and Raymond (NSE:RYMD) James have both expressed confidence in Alignment Healthcare’s future, with Piper Sandler raising its price target to $21 and maintaining an Overweight rating, while Raymond James increased its target to $19 and reiterated a Strong Buy rating. The company achieved its first year of adjusted EBITDA profitability and demonstrated significant membership growth of 59% in 2024. For 2025, Alignment Healthcare forecasts revenue between $3.72 billion and $3.78 billion and expects adjusted gross profit to range from $415 million to $445 million. Additionally, the company anticipates membership to grow to between 227,000 and 233,000. Analysts from Piper Sandler emphasized the effectiveness of Alignment Healthcare’s strategies, while Raymond James highlighted the company’s robust performance and promising growth trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.